373 related articles for article (PubMed ID: 19364085)
1. Effect of omega-3 fatty acids on cardiovascular risk factors in patients with type 2 diabetes mellitus and hypertriglyceridemia: an open study.
De Luis DA; Conde R; Aller R; Izaola O; González Sagrado M; Perez Castrillón JL; Dueñas A; Romero E
Eur Rev Med Pharmacol Sci; 2009; 13(1):51-5. PubMed ID: 19364085
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
3. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
McKenney JM; Sica D
Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
[TBL] [Abstract][Full Text] [Related]
4. Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio.
Burns T; Maciejewski SR; Hamilton WR; Zheng M; Mooss AN; Hilleman DE
Pharmacotherapy; 2007 May; 27(5):633-8. PubMed ID: 17461697
[TBL] [Abstract][Full Text] [Related]
5. What can we expect from omega-3 fatty acids?
Chan EJ; Cho L
Cleve Clin J Med; 2009 Apr; 76(4):245-51. PubMed ID: 19339640
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of Omacor in severe hypertriglyceridemia.
Harris WS; Ginsberg HN; Arunakul N; Shachter NS; Windsor SL; Adams M; Berglund L; Osmundsen K
J Cardiovasc Risk; 1997; 4(5-6):385-91. PubMed ID: 9865671
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of the effects of omega-3 polyunsaturated fatty acids and Olbetam (Acipimox) in the treatment of hypertriglyceridemia].
Zák A; Zeman M; Vítková D
Cas Lek Cesk; 1994 Dec; 133(24):755-8. PubMed ID: 7834677
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment of N-3 PUFAS on plasma lipoprotein levels and fatty acid composition of total serum and erythrocyte lipids in hypertriglyceridemic patients.
Putadechakum S; Tanphaichitr V; Leelahagul P; Pakpeankitvatana V; Surapisitchart T; Komindr S
J Med Assoc Thai; 2005 Feb; 88(2):181-6. PubMed ID: 15962668
[TBL] [Abstract][Full Text] [Related]
9. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
Bays HE; Tighe AP; Sadovsky R; Davidson MH
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):391-409. PubMed ID: 18327998
[TBL] [Abstract][Full Text] [Related]
10. Relationship of omega-3 fatty acid supplementation to plasma lipid peroxidation in predialysis patients with hypertriglyceridaemia.
Richard MJ; Sirajeddine MK; Cordonnier D; Tricot F; Foulon T; Mouneimne A; Maurizi J
Eur J Med; 1993 Jan; 2(1):15-8. PubMed ID: 8257999
[TBL] [Abstract][Full Text] [Related]
11. Effect of eicosapentaenoic/docosahexaenoic fatty acids and soluble fibers on blood lipids of individuals classified into different levels of lipidemia.
Castro IA; Monteiro VC; Barroso LP; Bertolami MC
Nutrition; 2007 Feb; 23(2):127-37. PubMed ID: 17234506
[TBL] [Abstract][Full Text] [Related]
12. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of omega-3 fatty acid supplementation on serum levels of tumour necrosis factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients.
Malekshahi Moghadam A; Saedisomeolia A; Djalali M; Djazayery A; Pooya S; Sojoudi F
Singapore Med J; 2012 Sep; 53(9):615-9. PubMed ID: 23023905
[TBL] [Abstract][Full Text] [Related]
14. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
Wu TJ; Ou HY; Chou CW; Hsiao SH; Lin CY; Kao PC
Ann Clin Lab Sci; 2007; 37(2):158-66. PubMed ID: 17522372
[TBL] [Abstract][Full Text] [Related]
15. [The hypotriglyceridemic effects of polyunsaturated fatty acids: pathogenetic hypothesis].
Del Ponte A; Bitti G; Di Giacomo G; Marinari S
Riv Eur Sci Med Farmacol; 1995; 17(5):175-82. PubMed ID: 8766785
[TBL] [Abstract][Full Text] [Related]
16. [Use of biologically active supplement containing omega-3 polyunsaturated fatty acids in patients with type 2 diabetes mellitus].
Isaev VA; Panchenko VM; Liutova LV; Karabasova MA
Vopr Pitan; 2004; 73(1):16-9. PubMed ID: 15049151
[TBL] [Abstract][Full Text] [Related]
17. Triglyceride profile in dyslipidaemia of type 2 diabetes mellitus.
Khan SR; Ayub N; Nawab S; Shamsi TS
J Coll Physicians Surg Pak; 2008 May; 18(5):270-3. PubMed ID: 18541079
[TBL] [Abstract][Full Text] [Related]
18. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
Maki KC; McKenney JM; Reeves MS; Lubin BC; Dicklin MR
Am J Cardiol; 2008 Aug; 102(4):429-33. PubMed ID: 18678300
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients.
Celik S; Doesch A; Erbel C; Blessing E; Ammon K; Koch A; Katus HA; Dengler TJ
Transplantation; 2008 Jul; 86(2):245-50. PubMed ID: 18645486
[TBL] [Abstract][Full Text] [Related]
20. [Effect of short-term use of omega-3-type polyunsaturated fatty acids in subjects with hypertriglyceridemia].
Naber FB; Oudkerk Pool M; Teerlink T; Popp-Snijders C; Gans RO; Bilo HJ
Ned Tijdschr Geneeskd; 1992 Aug; 136(31):1511-4. PubMed ID: 1495569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
